In vitro assays for the functional characterization of (psychedelic) substances at the serotonin receptor 5-HT
5-HT2AR
GPCR
hallucinogens
in vitro assay
psychedelics
serotonin
Journal
Journal of neurochemistry
ISSN: 1471-4159
Titre abrégé: J Neurochem
Pays: England
ID NLM: 2985190R
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
24
12
2021
received:
30
10
2021
accepted:
29
12
2021
pubmed:
4
1
2022
medline:
6
7
2022
entrez:
3
1
2022
Statut:
ppublish
Résumé
Serotonergic psychedelics are substances that induce alterations in mood, perception, and thought, and have the activation of serotonin (5-HT) 2A receptors (5-HT
Substances chimiques
Central Nervous System Agents
0
Hallucinogens
0
Receptor, Serotonin, 5-HT2A
0
Receptors, Serotonin
0
Serotonin 5-HT2 Receptor Agonists
0
Serotonin
333DO1RDJY
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
39-59Informations de copyright
© 2022 International Society for Neurochemistry.
Références
Abbas, A. I., Yadav, P. N., Yao, W. D., Arbuckle, M. I., Grant, S. G., Caron, M. G., & Roth, B. L. (2009). PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 29, 7124-7136. https://doi.org/10.1523/JNEUROSCI.1090-09.2009
Adham, N., Ellerbrock, B., Hartig, P., Weinshank, R. L., & Branchek, T. (1993). Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor expression system. Molecular Pharmacology, 43, 427-433.
Allen, J. A., Yadav, P. N., Setola, V., Farrell, M., & Roth, B. L. (2011). Schizophrenia risk gene CAV1 is both pro-psychotic and required for atypical antipsychotic drug actions in vivo. Translational Psychiatry, 1, e33. https://doi.org/10.1038/tp.2011.35
Almaula, N., Ebersole, B. J., Zhang, D., Weinstein, H., & Sealfon, S. C. (1996). Mapping the binding site pocket of the serotonin 5-Hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin. The Journal of Biological Chemistry, 271, 14672-14675. https://doi.org/10.1074/jbc.271.25.14672
Andersen, K. A. A., Carhart-Harris, R., Nutt, D. J., & Erritzoe, D. (2021). Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatrica Scandinavica, 143, 101-118. https://doi.org/10.1111/acps.13249
Arunotayanun, W., Dalley, J. W., Huang, X. P., Setola, V., Treble, R., Iversen, L., Roth, B. L., & Gibbons, S. (2013). An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: Emerging ‘Novel Psychoactive Drugs'. Bioorganic & Medicinal Chemistry Letters, 23, 3411-3415. https://doi.org/10.1016/j.bmcl.2013.03.066
Astrand, A., Guerrieri, D., Vikingsson, S., Kronstrand, R., & Green, H. (2020). In vitro characterization of new psychoactive substances at the mu-opioid, CB1, 5HT1A, and 5-HT2A receptors-On-target receptor potency and efficacy, and off-target effects. Forensic Science International, 317, 110553.
Banerjee, A. A., & Vaidya, V. A. (2020). Differential signaling signatures evoked by DOI versus lisuride stimulation of the 5-HT2A receptor. Biochemical and Biophysical Research Communications, 531, 609-614. https://doi.org/10.1016/j.bbrc.2020.08.022
Barclay, Z., Dickson, L., Robertson, D. N., Johnson, M. S., Holland, P. J., Rosie, R., Sun, L., Fleetwood-Walker, S., Lutz, E. M., & Mitchell, R. (2011). 5-HT2A receptor signalling through phospholipase D1 associated with its C-terminal tail. The Biochemical Journal, 436, 651-660. https://doi.org/10.1042/BJ20101844
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., Di Giovanni, G., Goodfellow, N. M., Halberstadt, A. L., Hartley, R. M., Hassaine, G., Herrick-Davis, K., Hovius, R., Lacivita, E., Lambe, E. K., … Hoyer, D. (2021). International union of basic and clinical pharmacology. CX. classification of receptors for 5-hydroxytryptamine; pharmacology and function. Pharmacological Reviews, 73, 310-520. https://doi.org/10.1124/pr.118.015552
Berg, K. A., Clarke, W. P., Chen, Y., Ebersole, B. J., McKay, R. D., & Maayani, S. (1994). 5-Hydroxytryptamine type 2A receptors regulate cyclic AMP accumulation in a neuronal cell line by protein kinase C-dependent and calcium/calmodulin-dependent mechanisms. Molecular Pharmacology, 45, 826-836.
Berg, K. A., Clarke, W. P., Sailstad, C., Saltzman, A., & Maayani, S. (1994). Signal transduction differences between 5-hydroxytryptamine type 2A and type 2C receptor systems. Molecular Pharmacology, 46, 477-484.
Berg, K. A., Harvey, J. A., Spampinato, U., & Clarke, W. P. (2005). Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors. Trends in Pharmacological Sciences, 26, 625-630. https://doi.org/10.1016/j.tips.2005.10.008
Berg, K. A., Maayani, S., Goldfarb, J., Scaramellini, C., Leff, P., & Clarke, W. P. (1998). Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus. Molecular Pharmacology, 54, 94-104. https://doi.org/10.1124/mol.54.1.94
Berridge, M. J., Downes, C. P., & Hanley, M. R. (1982). Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. The Biochemical Journal, 206, 587-595. https://doi.org/10.1042/bj2060587
Bhatnagar, A., Sheffler, D. J., Kroeze, W. K., Compton-Toth, B., & Roth, B. L. (2004). Caveolin-1 interacts with 5-HT2A serotonin receptors and profoundly modulates the signaling of selected Galphaq-coupled protein receptors. The Journal of Biological Chemistry, 279, 34614-34623.
Bhattacharya, A., Sankar, S., & Panicker, M. M. (2010). Differences in the C-terminus contribute to variations in trafficking between rat and human 5-HT(2A) receptor isoforms: Identification of a primate-specific tripeptide ASK motif that confers GRK-2 and beta arrestin-2 interactions. Journal of Neurochemistry, 112, 723-732.
Blair, J. B., Kurrasch-Orbaugh, D., Marona-Lewicka, D., Cumbay, M. G., Watts, V. J., Barker, E. L., & Nichols, D. E. (2000). Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. Journal of Medicinal Chemistry, 43, 4701-4710. https://doi.org/10.1021/jm000339w
Blinks, J. R. (1990). Use of photoproteins as intracellular calcium indicators. Environmental Health Perspectives, 84, 75-81. https://doi.org/10.1289/ehp.908475
Blough, B. E., Landavazo, A., Decker, A. M., Partilla, J. S., Baumann, M. H., & Rothman, R. B. (2014). Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes. Psychopharmacology (Berl), 231, 4135-4144. https://doi.org/10.1007/s00213-014-3557-7
Bogenschutz, M. P., & Ross, S. (2018). Therapeutic applications of classic hallucinogens. Current Topics in Behavioral Neurosciences, 36, 361-391.
Bohn, L. M., & McDonald, P. H. (2010). Seeking ligand bias: Assessing GPCR coupling to beta-arrestins for drug discovery. Drug discovery today. Technologies, 7, e37-e42.
Braden, M. R., & Nichols, D. E. (2007). Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor. Molecular Pharmacology, 72, 1200-1209.
Braden, M. R., Parrish, J. C., Naylor, J. C., & Nichols, D. E. (2006). Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Molecular Pharmacology, 70, 1956-1964.
Brandish, P. E., Hill, L. A., Zheng, W., & Scolnick, E. M. (2003). Scintillation proximity assay of inositol phosphates in cell extracts: High-throughput measurement of G-protein-coupled receptor activation. Analytical Biochemistry, 313, 311-318. https://doi.org/10.1016/S0003-2697(02)00630-9
Brandt, S. D., Kavanagh, P. V., Twamley, B., Westphal, F., Elliott, S. P., Wallach, J., Stratford, A., Klein, L. M., McCorvy, J. D., Nichols, D. E., & Halberstadt, A. L. (2018). Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). Drug Testing and Analysis, 10, 310-322. https://doi.org/10.1002/dta.2222
Bylund, D. B., & Toews, M. L. (1993). Radioligand binding methods: Practical guide and tips. The American Journal of Physiology, 265, L421-429. https://doi.org/10.1152/ajplung.1993.265.5.L421
Canal, C. E. (2018). Serotonergic psychedelics: experimental approaches for assessing mechanisms of action. Handbook of Experimental Pharmacology, 252, 227-260.
Canal, C. E., Cordova-Sintjago, T., Liu, Y., Kim, M. S., Morgan, D., & Booth, R. G. (2013). Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands. The Journal of Pharmacology and Experimental Therapeutics, 347, 705-716. https://doi.org/10.1124/jpet.113.208637
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. The New England Journal of Medicine, 384, 1402-1411. https://doi.org/10.1056/NEJMoa2032994
Carhart-Harris, R. L., & Goodwin, G. M. (2017). The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 42, 2105-2113.
Carpenter, B., & Tate, C. G. (2016). Engineering a minimal G protein to facilitate crystallisation of G protein-coupled receptors in their active conformation. Protein Engineering, Design & Selection: PEDS, 29, 583-594. https://doi.org/10.1093/protein/gzw049
Chambers, J. J., Kurrasch-Orbaugh, D. M., Parker, M. A., & Nichols, D. E. (2001). Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists. Journal of Medicinal Chemistry, 44, 1003-1010.
Chambers, J. J., Parrish, J. C., Jensen, N. H., Kurrasch-Orbaugh, D. M., Marona-Lewicka, D., & Nichols, D. E. (2003). Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands. Journal of Medicinal Chemistry, 46, 3526-3535.
Charlton, S. J., & Vauquelin, G. (2010). Elusive equilibrium: The challenge of interpreting receptor pharmacology using calcium assays. British Journal of Pharmacology, 161, 1250-1265. https://doi.org/10.1111/j.1476-5381.2010.00863.x
Conn, P. J., & Sanders-Bush, E. (1984). Selective 5HT-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex. Neuropharmacology, 23, 993-996. https://doi.org/10.1016/0028-3908(84)90017-0
Cussac, D., Boutet-Robinet, E., Ailhaud, M. C., Newman-Tancredi, A., Martel, J. C., Danty, N., & Rauly-Lestienne, I. (2008). Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. European Journal of Pharmacology, 594, 32-38. https://doi.org/10.1016/j.ejphar.2008.07.040
DeLapp, N. W., Gough, W. H., Kahl, S. D., Porter, A. C., & Wiernicki, T. R. (2012). GTPgammaS binding assays. In S. Markossian, A. Grossman, K. Brimacombe, M. Arkin, D. Auld, C. P. Austin, J. Baell, T. D. Y. Chung, N. P. Coussens, J. L. Dahlin, V. Devanarayan, T.L. Foley, M. Glicksman, M. D. Hall, J. V. Haas, S. R. J. Hoare, J. Inglese, P. W. Iversen, S. C. Kales, … X. Xu (Eds.), Assay guidance Manual. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences.
DeLapp, N. W., McKinzie, J. H., Sawyer, B. D., Vandergriff, A., Falcone, J., McClure, D., & Felder, C. C. (1999). Determination of [35S]guanosine-5'-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay. The Journal of Pharmacology and Experimental Therapeutics, 289, 946-955.
Dixon, A. S., Schwinn, M. K., Hall, M. P., Zimmerman, K., Otto, P., Lubben, T. H., Butler, B. L., Binkowski, B. F., Machleidt, T., Kirkland, T. A., Wood, M. G., Eggers, C. T., Encell, L. P., & Wood, K. V. (2016). NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. ACS Chemical Biology, 11, 400-408. https://doi.org/10.1021/acschembio.5b00753
Dong, C., Ly, C., Dunlap, L. E., Vargas, M. V., Sun, J., Hwang, I.-W., Azinfar, A., Oh, W. C., Wetsel, W. C., Olson, D. E., & Tian, L. (2021). Psychedelic-inspired drug discovery using an engineered biosensor. Cell, 184(2779-2792), e2718. https://doi.org/10.1016/j.cell.2021.03.043
Dowd, C. S., Herrick-Davis, K., Egan, C., DuPre, A., Smith, C., Teitler, M., & Glennon, R. A. (2000). 1-[4-(3-Phenylalkyl)phenyl]-2-aminopropanes as 5-HT(2A) partial agonists. Journal of Medicinal Chemistry, 43, 3074-3084.
Ebersole, B. J., Visiers, I., Weinstein, H., & Sealfon, S. C. (2003). Molecular basis of partial agonism: Orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy. Molecular Pharmacology, 63, 36-43. https://doi.org/10.1124/mol.63.1.36
Egan, C., Grinde, E., Dupre, A., Roth, B. L., Hake, M., Teitler, M., & Herrick-Davis, K. (2000). Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse (New York, N.Y.), 35, 144-150.
Egan, C. T., Herrick-Davis, K., Miller, K., Glennon, R. A., & Teitler, M. (1998). Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors. Psychopharmacology (Berl), 136, 409-414. https://doi.org/10.1007/s002130050585
Elmore, J. S., Decker, A. M., Sulima, A., Rice, K. C., Partilla, J. S., Blough, B. E., & Baumann, M. H. (2018). Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats. Neuropharmacology, 142, 240-250. https://doi.org/10.1016/j.neuropharm.2018.02.033
Eshleman, A. J., Forster, M. J., Wolfrum, K. M., Johnson, R. A., Janowsky, A., & Gatch, M. B. (2014). Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: Mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. Psychopharmacology (Berl), 231, 875-888. https://doi.org/10.1007/s00213-013-3303-6
Eshleman, A. J., Wolfrum, K. M., Reed, J. F., Kim, S. O., Johnson, R. A., & Janowsky, A. (2018). Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors. Biochemical Pharmacology, 158, 27-34. https://doi.org/10.1016/j.bcp.2018.09.024
Ettrup, A., Hansen, M., Santini, M. A., Paine, J., Gillings, N., Palner, M., Lehel, S., Herth, M. M., Madsen, J., Kristensen, J., Begtrup, M., & Knudsen, G. M. (2011). Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers. European Journal of Nuclear Medicine and Molecular Imaging, 38, 681-693. https://doi.org/10.1007/s00259-010-1686-8
Ettrup, A., Palner, M., Gillings, N. et al (2010). Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, 51, 1763-1770.
Felder, C. C., Kanterman, R. Y., Ma, A. L., & Axelrod, J. (1990). Serotonin stimulates phospholipase A2 and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis. Proceedings of the National Academy of Sciences of the United States of America, 87, 2187-2191. https://doi.org/10.1073/pnas.87.6.2187
Feng, Z., Mohapatra, S., Klimko, P. G., Hellberg, M. R., May, J. A., Kelly, C., Williams, G., McLaughlin, M. A., & Sharif, N. A. (2007). Novel benzodifuran analogs as potent 5-HT2A receptor agonists with ocular hypotensive activity. Bioorganic & Medicinal Chemistry Letters, 17, 2998-3002. https://doi.org/10.1016/j.bmcl.2007.03.073
Fitzgerald, L. W., Conklin, D. S., Krause, C. M., Marshall, A. P., Patterson, J. P., Tran, D. P., Iyer, G., Kostich, W. A., Largent, B. L., & Hartig, P. R. (1999). High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: Evidence favoring the ternary complex and two-state models of agonist action. Journal of Neurochemistry, 72, 2127-2134. https://doi.org/10.1046/j.1471-4159.1999.0722127.x
Flanagan, T. W., Billac, G. B., Landry, A. N., Sebastian, M. N., Cormier, S. A., & Nichols, C. D. (2021). Structure-activity relationship analysis of psychedelics in a rat model of asthma reveals the anti-inflammatory pharmacophore. ACS Pharmacology & Translational Science, 4, 488-502. https://doi.org/10.1021/acsptsci.0c00063
Florian, J. A., & Watts, S. W. (1998). Integration of mitogen-activated protein kinase kinase activation in vascular 5-hydroxytryptamine2A receptor signal transduction. The Journal of Pharmacology and Experimental Therapeutics, 284, 346-355.
Garcia-Bea, A., Miranda-Azpiazu, P., Muguruza, C. et al (2019). Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via Galphai1-proteins. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 29, 1453-1463.
Gatch, M. B., Forster, M. J., Janowsky, A., & Eshleman, A. J. (2011). Abuse liability profile of three substituted tryptamines. The Journal of Pharmacology and Experimental Therapeutics, 338, 280-289. https://doi.org/10.1124/jpet.111.179705
Gelber, E. I., Kroeze, W. K., Willins, D. L., Gray, J. A., Sinar, C. A., Hyde, E. G., Gurevich, V., Benovic, J., & Roth, B. L. (1999). Structure and function of the third intracellular loop of the 5-hydroxytryptamine2A receptor: The third intracellular loop is alpha-helical and binds purified arrestins. Journal of Neurochemistry, 72, 2206-2214.
Glennon, R. A., Bondarev, M. L., Khorana, N., Young, R., May, J. A., Hellberg, M. R., McLaughlin, M. A., & Sharif, N. A. (2004). Beta-oxygenated analogues of the 5-HT2A serotonin receptor agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. Journal of Medicinal Chemistry, 47, 6034-6041.
Glennon, R. A., Dukat, M., Grella, B. et al (2000). Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug and Alcohol Dependence, 60, 121-132.
Glennon, R. A., Titeler, M., & McKenney, J. D. (1984). Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sciences, 35, 2505-2511. https://doi.org/10.1016/0024-3205(84)90436-3
González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., Gingrich, J. A., Filizola, M., Meana, J. J., & Sealfon, S. C. (2008). Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 452, 93-97. https://doi.org/10.1038/nature06612
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., Sealfon, S. C., & Gingrich, J. A. (2007). Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron, 53, 439-452. https://doi.org/10.1016/j.neuron.2007.01.008
González-Maeso, J., Yuen, T., Ebersole, B. J., Wurmbach, E., Lira, A., Zhou, M., Weisstaub, N., Hen, R., Gingrich, J. A., & Sealfon, S. C. (2003). Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 23, 8836-8843. https://doi.org/10.1523/JNEUROSCI.23-26-08836.2003
Gray, J. A., Bhatnagar, A., Gurevich, V. V., & Roth, B. L. (2003). The interaction of a constitutively active arrestin with the arrestin-insensitive 5-HT(2A) receptor induces agonist-independent internalization. Molecular Pharmacology, 63, 961-972.
Grynkiewicz, G., Poenie, M., & Tsien, R. Y. (1985). A new generation of Ca2+ indicators with greatly improved fluorescence properties. The Journal of Biological Chemistry, 260, 3440-3450. https://doi.org/10.1016/S0021-9258(19)83641-4
Halberstadt, A. L. (2015). Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioural Brain Research, 277, 99-120. https://doi.org/10.1016/j.bbr.2014.07.016
Halberstadt, A. L. (2017). Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens. Current Topics in Behavioral Neurosciences, 32, 283-311.
Halberstadt, A. L., Chatha, M., Klein, A. K., McCorvy, J. D., Meyer, M. R., Wagmann, L., Stratford, A., & Brandt, S. D. (2020). Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD). Neuropharmacology, 172, 107856.
Halberstadt, A. L., Klein, L. M., Chatha, M., Valenzuela, L. B., Stratford, A., Wallach, J., Nichols, D. E., & Brandt, S. D. (2019). Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). Psychopharmacology (Berl), 236, 799-808. https://doi.org/10.1007/s00213-018-5055-9
Hansen, M., Jacobsen, S. E., Plunkett, S., Liebscher, G. E., McCorvy, J. D., Brauner-Osborne, H., & Kristensen, J. L. (2015). Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists. Bioorganic & Medicinal Chemistry, 23, 3933-3937. https://doi.org/10.1016/j.bmc.2014.12.011
Hansen, M., Phonekeo, K., Paine, J. S., Leth-Petersen, S., Begtrup, M., Brauner-Osborne, H., & Kristensen, J. L. (2014). Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS Chemical Neuroscience, 5, 243-249.
Hermans, E. (2003). Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. Pharmacology & Therapeutics, 99, 25-44. https://doi.org/10.1016/S0163-7258(03)00051-2
Jensen, A. A., McCorvy, J. D., Leth-Petersen, S., Bundgaard, C., Liebscher, G., Kenakin, T. P., Brauner-Osborne, H., Kehler, J., & Kristensen, J. L. (2017). Detailed characterization of the in vitro pharmacological and pharmacokinetic properties of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-Cyanophenylethylamine (25CN-NBOH), a highly selective and brain-penetrant 5-HT2A receptor agonist. The Journal of Pharmacology and Experimental Therapeutics, 361, 441-453.
Jerman, J. C., Brough, S. J., Gager, T., Wood, M., Coldwell, M. C., Smart, D., & Middlemiss, D. N. (2001). Pharmacological characterisation of human 5-HT2 receptor subtypes. European Journal of Pharmacology, 414, 23-30. https://doi.org/10.1016/S0014-2999(01)00775-0
Johnson, M. P., Audia, J. E., Nissen, J. S., & Nelson, D. L. (1993). N(1)-substituted ergolines and tryptamines show species differences for the agonist-labeled 5-HT2 receptor. European Journal of Pharmacology, 239, 111-118. https://doi.org/10.1016/0014-2999(93)90983-O
Johnson, M. P., Loncharich, R. J., Baez, M., & Nelson, D. L. (1994). Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Molecular Pharmacology, 45, 277-286.
Juncosa, J. I. Jr, Hansen, M., Bonner, L. A., Cueva, J. P., Maglathlin, R., McCorvy, J. D., Marona-Lewicka, D., Lill, M. A., & Nichols, D. E. (2013). Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands. ACS Chemical Neuroscience, 4, 96-109.
Kadamur, G., & Ross, E. M. (2013). Mammalian phospholipase C. Annual Review of Physiology, 75, 127-154. https://doi.org/10.1146/annurev-physiol-030212-183750
Karaki, S., Becamel, C., Murat, S., Mannoury la Cour, C., Millan, M. J., Prezeau, L., Bockaert, J., Marin, P., & Vandermoere, F. (2014). Quantitative phosphoproteomics unravels biased phosphorylation of serotonin 2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic agonists. Molecular & Cellular Proteomics: MCP, 13, 1273-1285. https://doi.org/10.1074/mcp.M113.036558
Kenakin, T. (2015). Gaddum Memorial Lecture 2014: Receptors as an evolving concept: From switches to biased microprocessors. British Journal of Pharmacology, 172, 4238-4253. https://doi.org/10.1111/bph.13217
Kenakin, T. (2019). Biased receptor signaling in drug discovery. Pharmacological Reviews, 71, 267-315. https://doi.org/10.1124/pr.118.016790
Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., & Novick, S. (2012). A simple method for quantifying functional selectivity and agonist bias. ACS Chemical Neuroscience, 3, 193-203. https://doi.org/10.1021/cn200111m
Kim, K., Che, T., Panova, O., DiBerto, J. F., Lyu, J., Krumm, B. E., Wacker, D., Robertson, M. J., Seven, A. B., Nichols, D. E., Shoichet, B. K., Skiniotis, G., & Roth, B. L. (2020). Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor. Cell, 182(1574-1588), e1519. https://doi.org/10.1016/j.cell.2020.08.024
Klein, A. K., Chatha, M., Laskowski, L. J., Anderson, E. I., Brandt, S. D., Chapman, S. J., McCorvy, J. D., & Halberstadt, A. L. (2021). Investigation of the structure-activity relationships of psilocybin analogues. ACS Pharmacology & Translational Science, 4, 533-542. https://doi.org/10.1021/acsptsci.0c00176
Kolaczynska, K. E., Luethi, D., Trachsel, D., Hoener, M. C., & Liechti, M. E. (2019). Receptor interaction profiles of 4-alkoxy-substituted 2,5-dimethoxyphenethylamines and related amphetamines. Frontiers in Pharmacology, 10, 1423. https://doi.org/10.3389/fphar.2019.01423
Kolb, P., & Gloriam, D. (2021). International Union of Basic and Clinical Pharmacology. Recommendations for GPCR ligand bias. Authorea preprint. https://doi.org/10.22541/au.163129851.17708337/v1
Kroeze, W. K., Sassano, M. F., Huang, X. P., Lansu, K., McCorvy, J. D., Giguere, P. M., Sciaky, N., & Roth, B. L. (2015). PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nature Structural & Molecular Biology, 22, 362-369. https://doi.org/10.1038/nsmb.3014
Kurrasch-Orbaugh, D. M., Parrish, J. C., Watts, V. J., & Nichols, D. E. (2003). A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: The involvement of MAP kinases. Journal of Neurochemistry, 86, 980-991. https://doi.org/10.1046/j.1471-4159.2003.01921.x
Kurrasch-Orbaugh, D. M., Watts, V. J., Barker, E. L., & Nichols, D. E. (2003). Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. The Journal of Pharmacology and Experimental Therapeutics, 304, 229-237.
Lane, J. R., May, L. T., Parton, R. G., Sexton, P. M., & Christopoulos, A. (2017). A kinetic view of GPCR allostery and biased agonism. Nature Chemical Biology, 13, 929-937. https://doi.org/10.1038/nchembio.2431
Leth-Petersen, S., Petersen, I. N., Jensen, A. A., Bundgaard, C., Baek, M., Kehler, J., & Kristensen, J. L. (2016). 5-HT2A/5-HT2C receptor pharmacology and intrinsic clearance of N-benzylphenethylamines modified at the primary site of metabolism. ACS Chemical Neuroscience, 7, 1614-1619.
Lohse, M. J., Nuber, S., & Hoffmann, C. (2012). Fluorescence/bioluminescence resonance energy transfer techniques to study G-protein-coupled receptor activation and signaling. Pharmacological Reviews, 64, 299-336. https://doi.org/10.1124/pr.110.004309
Lopez-Gimenez, J. F., & Gonzalez-Maeso, J. (2018). Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. Current Topics in Behavioral Neurosciences, 36, 45-73.
Luethi, D., & Liechti, M. E. (2018). Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. The International Journal of Neuropsychopharmacology, 21, 926-931. https://doi.org/10.1093/ijnp/pyy047
Luethi, D., & Liechti, M. E. (2020). Designer drugs: Mechanism of action and adverse effects. Archives of Toxicology, 94, 1085-1133. https://doi.org/10.1007/s00204-020-02693-7
Luethi, D., Trachsel, D., Hoener, M. C., & Liechti, M. E. (2018). Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs). Neuropharmacology, 134, 141-148. https://doi.org/10.1016/j.neuropharm.2017.07.012
Luethi, D., Widmer, R., Trachsel, D., Hoener, M. C., & Liechti, M. E. (2019). Monoamine receptor interaction profiles of 4-aryl-substituted 2,5-dimethoxyphenethylamines (2C-BI derivatives). European Journal of Pharmacology, 855, 103-111. https://doi.org/10.1016/j.ejphar.2019.05.014
Maguire, J. J., Kuc, R. E., & Davenport, A. P. (2012). Radioligand binding assays and their analysis. Methods in Molecular Biology (Clifton. N.J.), 897, 31-77.
Manchanda, Y., Ramchunder, Z., Shchepinova, M. M., Rutter, G. A., Inoue, A., Tate, E. W., Jones, B., & Tomas, A. (2021). Expression of mini-G proteins specifically halt cognate GPCR trafficking and intracellular signalling. BioRxiv Preprint. https://doi.org/10.1101/2021.11.24.469908
Marcher-Rorsted, E., Halberstadt, A. L., Klein, A. K., Chatha, M., Jademyr, S., Jensen, A. A., & Kristensen, J. L. (2020). Investigation of the 2,5-dimethoxy motif in phenethylamine serotonin 2A receptor agonists. ACS Chemical Neuroscience, 11, 1238-1244.
Marona-Lewicka, D., Kurrasch-Orbaugh, D. M., Selken, J. R., Cumbay, M. G., Lisnicchia, J. G., & Nichols, D. E. (2002). Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats. Psychopharmacology (Berl), 164, 93-107.
Maroteaux, L., Ayme-Dietrich, E., Aubertin-Kirch, G., Banas, S., Quentin, E., Lawson, R., & Monassier, L. (2017). New therapeutic opportunities for 5-HT2 receptor ligands. Pharmacology & Therapeutics, 170, 14-36. https://doi.org/10.1016/j.pharmthera.2016.10.008
Marti-Solano, M., Iglesias, A., de Fabritiis, G., Sanz, F., Brea, J., Loza, M. I., Pastor, M., & Selent, J. (2015). Detection of new biased agonists for the serotonin 5-HT2A receptor: Modeling and experimental validation. Molecular Pharmacology, 87, 740-746.
May, J. A., Chen, H. H., Rusinko, A., Lynch, V. M., Sharif, N. A., & McLaughlin, M. A. (2003). A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole. Journal of Medicinal Chemistry, 46, 4188-4195.
May, J. A., Dantanarayana, A. P., Zinke, P. W., McLaughlin, M. A., & Sharif, N. A. (2006). 1-((S)-2-aminopropyl)-1H-indazol-6-ol: A potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. Journal of Medicinal Chemistry, 49, 318-328.
May, J. A., McLaughlin, M. A., Sharif, N. A., Hellberg, M. R., & Dean, T. R. (2003). Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. The Journal of Pharmacology and Experimental Therapeutics, 306, 301-309.
May, J. A., Sharif, N. A., Chen, H.-H., Liao, J. C., Kelly, C. R., Glennon, R. A., Young, R., Li, J.-X., Rice, K. C., & France, C. P. (2009). Pharmacological properties and discriminative stimulus effects of a novel and selective 5-HT2 receptor agonist AL-38022A [(S)-2-(8,9-dihydro-7H-pyrano[2,3-g]indazol-1-yl)-1-methylethylamine]. Pharmacology, Biochemistry, and Behavior, 91, 307-314. https://doi.org/10.1016/j.pbb.2008.07.015
McLean, T. H., Chambers, J. J., Parrish, J. C., Braden, M. R., Marona-Lewicka, D., Kurrasch-Orbaugh, D., & Nichols, D. E. (2006). C-(4,5,6-trimethoxyindan-1-yl)methanamine: A mescaline analogue designed using a homology model of the 5-HT2A receptor. Journal of Medicinal Chemistry, 49, 4269-4274.
McLean, T. H., Parrish, J. C., Braden, M. R., Marona-Lewicka, D., Gallardo-Godoy, A., & Nichols, D. E. (2006). 1-Aminomethylbenzocycloalkanes: Conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. Journal of Medicinal Chemistry, 49, 5794-5803.
Millan, M. J., Marin, P., Bockaert, J., & Mannoury la Cour, C. (2008). Signaling at G-protein-coupled serotonin receptors: Recent advances and future research directions. Trends in Pharmacological Sciences, 29, 454-464. https://doi.org/10.1016/j.tips.2008.06.007
Milligan, G. (2003). Principles: Extending the utility of [35S]GTP gamma S binding assays. Trends in Pharmacological Sciences, 24, 87-90.
Minta, A., Kao, J. P., & Tsien, R. Y. (1989). Fluorescent indicators for cytosolic calcium based on rhodamine and fluorescein chromophores. The Journal of Biological Chemistry, 264, 8171-8178. https://doi.org/10.1016/S0021-9258(18)83165-9
Monte, A. P., Marona-Lewicka, D., Kanthasamy, A., Sanders-Bush, E., & Nichols, D. E. (1995). Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. Journal of Medicinal Chemistry, 38, 958-966. https://doi.org/10.1021/jm00006a015
Monte, A. P., Waldman, S. R., Marona-Lewicka, D., Wainscott, D. B., Nelson, D. L., Sanders-Bush, E., & Nichols, D. E. (1997). Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. Journal of Medicinal Chemistry, 40, 2997-3008. https://doi.org/10.1021/jm970219x
Moya, P. R., Berg, K. A., Gutierrez-Hernandez, M. A., Saez-Briones, P., Reyes-Parada, M., Cassels, B. K., & Clarke, W. P. (2007). Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. The Journal of Pharmacology and Experimental Therapeutics, 321, 1054-1061.
Nehme, R., Carpenter, B., Singhal, A., Strege, A., Edwards, P. C., White, C. F., Du, H., Grisshammer, R., & Tate, C. G. (2017). Mini-G proteins: Novel tools for studying GPCRs in their active conformation. PLoS One, 12, e0175642.
Neubig, R. R., Spedding, M., Kenakin, T., Christopoulos, A. & International Union of Pharmacology Committee on Receptor, N. and Drug, C (2003). International union of pharmacology committee on receptor nomenclature and drug classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacological Reviews, 55, 597-606.
Newman-Tancredi, A., Cussac, D., Quentric, Y., Touzard, M., Verriele, L., Carpentier, N., & Millan, M. J. (2002). Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. The Journal of Pharmacology and Experimental Therapeutics, 303, 815-822.
Newton, R. A., Phipps, S. L., Flanigan, T. P., Newberry, N. R., Carey, J. E., Kumar, C., McDonald, B., Chen, C., & Elliott, J. M. (1996). Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: Comparative stimulation by hallucinogenic drugs. Journal of Neurochemistry, 67, 2521-2531. https://doi.org/10.1046/j.1471-4159.1996.67062521.x
Nichols, D. E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101, 131-181. https://doi.org/10.1016/j.pharmthera.2003.11.002
Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68, 264-355. https://doi.org/10.1124/pr.115.011478
Nichols, D. E. (2018). Chemistry and structure-activity relationships of psychedelics. Current Topics in Behavioral Neurosciences, 36, 1-43.
Nichols, D. E., Frescas, S., Marona-Lewicka, D., Huang, X., Roth, B. L., Gudelsky, G. A., & Nash, J. F. (1994). 1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: A potent serotonin 5-HT2A/2C agonist. Journal of Medicinal Chemistry, 37, 4346-4351. https://doi.org/10.1021/jm00051a011
Nichols, D. E., Frescas, S., Marona-Lewicka, D., & Kurrasch-Orbaugh, D. M. (2002). Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N, N-diethyllysergamide (LSD). Journal of Medicinal Chemistry, 45, 4344-4349.
Nichols, D. E., & Nichols, C. D. (2008). Serotonin receptors. Chemical Reviews, 108, 1614-1641.
Nichols, D. E., Sassano, M. F., Halberstadt, A. L., Klein, L. M., Brandt, S. D., Elliott, S. P., & Fiedler, W. J. (2015). N-benzyl-5-methoxytryptamines as potent serotonin 5-HT2 receptor family agonists and comparison with a series of phenethylamine analogues. ACS Chemical Neuroscience, 6, 1165-1175.
Nickolls, S. A., Waterfield, A., Williams, R. E., & Kinloch, R. A. (2011). Understanding the effect of different assay formats on agonist parameters: A study using the mu-opioid receptor. Journal of Biomolecular Screening, 16, 706-716.
Norskov-Lauritsen, L., Thomsen, A. R., & Brauner-Osborne, H. (2014). G protein-coupled receptor signaling analysis using homogenous time-resolved Forster resonance energy transfer (HTRF(R)) technology. International Journal of Molecular Sciences, 15, 2554-2572.
Olsen, R. H. J., DiBerto, J. F., English, J. G., Glaudin, A. M., Krumm, B. E., Slocum, S. T., Che, T., Gavin, A. C., McCorvy, J. D., Roth, B. L., & Strachan, R. T. (2020). TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome. Nature Chemical Biology, 16, 841-849. https://doi.org/10.1038/s41589-020-0535-8
Onaran, H. O., Ambrosio, C., Ugur, O., Madaras Koncz, E., Gro, M. C., Vezzi, V., Rajagopal, S., & Costa, T. (2017). Systematic errors in detecting biased agonism: Analysis of current methods and development of a new model-free approach. Scientific Reports, 7, 44247. https://doi.org/10.1038/srep44247
Oufkir, T., Arseneault, M., Sanderson, J. T., & Vaillancourt, C. (2010). The 5-HT 2A serotonin receptor enhances cell viability, affects cell cycle progression and activates MEK-ERK1/2 and JAK2-STAT3 signalling pathways in human choriocarcinoma cell lines. Placenta, 31, 439-447. https://doi.org/10.1016/j.placenta.2010.02.019
Parrish, J. C., Braden, M. R., Gundy, E., & Nichols, D. E. (2005). Differential phospholipase C activation by phenylalkylamine serotonin 5-HT 2A receptor agonists. Journal of Neurochemistry, 95, 1575-1584. https://doi.org/10.1111/j.1471-4159.2005.03477.x
Parrish, J. C., & Nichols, D. E. (2006). Serotonin 5-HT(2A) receptor activation induces 2-arachidonoylglycerol release through a phospholipase c-dependent mechanism. Journal of Neurochemistry, 99, 1164-1175.
Patriarchi, T., Cho, J. R., Merten, K., Howe, M. W., Marley, A., Xiong, W.-H., Folk, R. W., Broussard, G. J., Liang, R., Jang, M. J., Zhong, H., Dombeck, D., von Zastrow, M., Nimmerjahn, A., Gradinaru, V., Williams, J. T., & Tian, L. (2018). Ultrafast neuronal imaging of dopamine dynamics with designed genetically encoded sensors. Science, 360(6396), eaat4422. https://doi.org/10.1126/science.aat4422
Peterson, Y. K., & Luttrell, L. M. (2017). The diverse roles of arrestin scaffolds in g protein-coupled receptor signaling. Pharmacological Reviews, 69, 256-297. https://doi.org/10.1124/pr.116.013367
Pfleger, K. D., & Eidne, K. A. (2006). Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET). Nature Methods, 3, 165-174. https://doi.org/10.1038/nmeth841
Pigott, A., Frescas, S., McCorvy, J. D., Huang, X. P., Roth, B. L., & Nichols, D. E. (2012). trans-2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and trans-2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT(2) receptor family. Beilstein Journal of Organic Chemistry, 8, 1705-1709.
Porter, R. H., Benwell, K. R., Lamb, H., Malcolm, C. S., Allen, N. H., Revell, D. F., Adams, D. R., & Sheardown, M. J. (1999). Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. British Journal of Pharmacology, 128, 13-20.
Pottie, E., Cannaert, A., & Stove, C. P. (2020). In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of beta-arrestin 2 recruitment to the serotonin 2A receptor. Archives of Toxicology, 94, 3449-3460.
Pottie, E., Cannaert, A., Van Uytfanghe, K., & Stove, C. P. (2019). Setup of a serotonin 2A receptor (5-HT2AR) bioassay: demonstration of its applicability to functionally characterize hallucinogenic new psychoactive substances and an explanation why 5-HT2AR bioassays are not suited for universal activity-based screening of biofluids for new psychoactive substances. Analytical Chemistry, 91, 15444-15452. https://doi.org/10.1021/acs.analchem.9b03104
Pottie, E., Dedecker, P., & Stove, C. P. (2020). Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of beta-arrestin 2 and miniGalphaq bioassays. Biochemical Pharmacology, 182, 114251.
Pottie, E., Kupriyanova, O. V., Brandt, A. L., Laprairie, R. B., Shevyrin, V. A., & Stove, C. P. (2021). Serotonin 2A receptor (5-HT2AR) activation by 25H-NBOMe positional isomers. In vitro functional evaluation and molecular docking. ACS Pharmacology & Translational Science, 4, 479-487.
Pottie, E., Kupriyanova, O. V., Shevyrin, V. A., & Stove, C. P. (2021). Synthesis and functional characterization of 2-(2,5-Dimethoxyphenyl)-N-(2-fluorobenzyl)ethanamine (25H-NBF) positional isomers. ACS Chemical Neuroscience, 12, 1667-1673.
Rabin, R. A., Regina, M., Doat, M., & Winter, J. C. (2002). 5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens. Pharmacology, Biochemistry, and Behavior, 72, 29-37. https://doi.org/10.1016/S0091-3057(01)00720-1
Rajagopal, S., Ahn, S., Rominger, D. H., Gowen-MacDonald, W., Lam, C. M., Dewire, S. M., Violin, J. D., & Lefkowitz, R. J. (2011). Quantifying ligand bias at seven-transmembrane receptors. Molecular Pharmacology, 80, 367-377. https://doi.org/10.1124/mol.111.072801
Raote, I., Bhattacharya, A., & Panicker, M. M. (2007) Serotonin 2A (5-HT2A) receptor function: Ligand-dependent mechanisms and pathways. In A. Chattopadhyay (Ed.), Serotonin receptors in neurobiology. Boca Raton (FL): CRC Press/Taylor & Francis.
Ray, T. S. (2010). Psychedelics and the human receptorome. PLoS One, 5, e9019. https://doi.org/10.1371/journal.pone.0009019
Raymond, J. R., Mukhin, Y. V., Gelasco, A., Turner, J., Collinsworth, G., Gettys, T. W., Grewal, J. S., & Garnovskaya, M. N. (2001). Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacology & Therapeutics, 92, 179-212. https://doi.org/10.1016/S0163-7258(01)00169-3
Rickli, A., Kopf, S., Hoener, M. C., & Liechti, M. E. (2015). Pharmacological profile of novel psychoactive benzofurans. British Journal of Pharmacology, 172, 3412-3425. https://doi.org/10.1111/bph.13128
Rickli, A., Luethi, D., Reinisch, J., Buchy, D., Hoener, M. C., & Liechti, M. E. (2015). Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology, 99, 546-553. https://doi.org/10.1016/j.neuropharm.2015.08.034
Robertson, D. N., Johnson, M. S., Moggach, L. O., Holland, P. J., Lutz, E. M., & Mitchell, R. (2003). Selective interaction of ARF1 with the carboxy-terminal tail domain of the 5-HT2A receptor. Molecular Pharmacology, 64, 1239-1250.
Roth, B. L., Choudhary, M. S., Khan, N., & Uluer, A. Z. (1997). High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: Evidence in favor of a modified ternary complex model. The Journal of Pharmacology and Experimental Therapeutics, 280, 576-583.
Roth, B. L., & Chuang, D. M. (1987). Multiple mechanisms of serotonergic signal transduction. Life Sciences, 41, 1051-1064. https://doi.org/10.1016/0024-3205(87)90621-7
Roth, B. L., Nakaki, T., Chuang, D. M., & Costa, E. (1984). Aortic recognition sites for serotonin (5HT) are coupled to phospholipase C and modulate phosphatidylinositol turnover. Neuropharmacology, 23, 1223-1225. https://doi.org/10.1016/0028-3908(84)90244-2
Roth, B. L., Nakaki, T., Chuang, D. M., & Costa, E. (1986). 5-Hydroxytryptamine2 receptors coupled to phospholipase C in rat aorta: Modulation of phosphoinositide turnover by phorbol ester. The Journal of Pharmacology and Experimental Therapeutics, 238, 480-485.
Roth, B. L., Shoham, M., Choudhary, M. S., & Khan, N. (1997). Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors. Molecular Pharmacology, 52, 259-266.
Rozenfeld, R., & Devi, L. A. (2011). Exploring a role for heteromerization in GPCR signalling specificity. The Biochemical Journal, 433, 11-18. https://doi.org/10.1042/BJ20100458
Sade, Y., Toker, L., Kara, N. Z., Einat, H., Rapoport, S., Moechars, D., Berry, G. T., Bersudsky, Y., & Agam, G. (2016). IP3 accumulation and/or inositol depletion: Two downstream lithium's effects that may mediate its behavioral and cellular changes. Translational Psychiatry, 6, e968. https://doi.org/10.1038/tp.2016.217
Sard, H., Kumaran, G., Morency, C., Roth, B. L., Toth, B. A., He, P., & Shuster, L. (2005). SAR of psilocybin analogs: Discovery of a selective 5-HT 2C agonist. Bioorganic & Medicinal Chemistry Letters, 15, 4555-4559. https://doi.org/10.1016/j.bmcl.2005.06.104
Schmid, C. L., & Bohn, L. M. (2018). βArrestins: ligand-directed regulators of 5-HT2A receptor trafficking and signaling events. In G. Di Giovanni, B. Guiard (Ed.), 5-HT2A receptors in the central nervous system. The receptors (Vol. 32, pp. 31-55). Humana Press.
Schmid, C. L., Raehal, K. M., & Bohn, L. M. (2008). Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proceedings of the National Academy of Sciences of the United States of America, 105, 1079-1084.
Schroeder, K. S., & Neagle, B. D. (1996). FLIPR: A new instrument for accurate, high throughput optical screening. Journal of Biomolecular Screening, 1, 75-80. https://doi.org/10.1177/108705719600100205
Schultz, D. M., Prescher, J. A., Kidd, S., Marona-Lewicka, D., Nichols, D. E., & Monte, A. (2008). ‘Hybridʹ benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines. Bioorganic & Medicinal Chemistry, 16, 6242-6251.
Shapiro, D. A., Kristiansen, K., Kroeze, W. K., & Roth, B. L. (2000). Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Molecular Pharmacology, 58, 877-886.
Smith, R. L., Canton, H., Barrett, R. J., & Sanders-Bush, E. (1998). Agonist properties of N, N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors. Pharmacology, Biochemistry, and Behavior, 61, 323-330. https://doi.org/10.1016/S0091-3057(98)00110-5
Sullivan, E., Tucker, E. M., & Dale, I. L. (1999). Measurement of [Ca2+] using the fluorometric imaging plate reader (FLIPR). Methods in Molecular Biology (Clifton, N.J.), 114, 125-133.
Thomsen, W., Frazer, J., & Unett, D. (2005). Functional assays for screening GPCR targets. Current Opinion in Biotechnology, 16, 655-665. https://doi.org/10.1016/j.copbio.2005.10.008
Trachsel, D., Nichols, D. E., Kidd, S., Hadorn, M., & Baumberger, F. (2009). 4-aryl-substituted 2,5-dimethoxyphenethylamines: Synthesis and serotonin 5-HT(2A) receptor affinities. Chemistry & Biodiversity, 6, 692-704.
Trinquet, E., Fink, M., Bazin, H., Grillet, F., Maurin, F., Bourrier, E., Ansanay, H., Leroy, C., Michaud, A., Durroux, T., Maurel, D., Malhaire, F., Goudet, C., Pin, J.-P., Naval, M., Hernout, O., Chrétien, F., Chapleur, Y., & Mathis, G. (2006). D-myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation. Analytical Biochemistry, 358, 126-135. https://doi.org/10.1016/j.ab.2006.08.002
Tsien, R. Y., Rink, T. J., & Poenie, M. (1985). Measurement of cytosolic free Ca2+ in individual small cells using fluorescence microscopy with dual excitation wavelengths. Cell Calcium, 6, 145-157. https://doi.org/10.1016/0143-4160(85)90041-7
Udenfriend, S., Weissbach, H., & Clark, C. T. (1955). The estimation of 5-hydroxytryptamine (serotonin) in biological tissues. The Journal of Biological Chemistry, 215, 337-344. https://doi.org/10.1016/S0021-9258(18)66041-7
UNODC (2020). Current NPS threats, Vol. 3.
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021). Psychedelics and other psychoplastogens for treating mental illness. Frontiers in Psychiatry, 12, 727117. https://doi.org/10.3389/fpsyt.2021.727117
Wacker, D., Wang, C., Katritch, V. et al (2013). Structural features for functional selectivity at serotonin receptors. Science (New York, N.Y.), 340, 615-619.
Wacker, D., Wang, S., McCorvy, J. D., Betz, R. M., Venkatakrishnan, A. J., Levit, A., Lansu, K., Schools, Z. L., Che, T., Nichols, D. E., Shoichet, B. K., Dror, R. O., & Roth, B. L. (2017). Crystal structure of an LSD-bound human serotonin receptor. Cell, 168(377-389), e312. https://doi.org/10.1016/j.cell.2016.12.033
Wan, Q., Okashah, N., Inoue, A., Nehme, R., Carpenter, B., Tate, C. G., & Lambert, N. A. (2018). Mini G protein probes for active G protein-coupled receptors (GPCRs) in live cells. The Journal of Biological Chemistry, 293, 7466-7473. https://doi.org/10.1074/jbc.RA118.001975
Whiteside, M. S., Kurrasch-Orbaugh, D., Marona-Lewicka, D., Nichols, D. E., & Monte, A. (2002). Substituted hexahydrobenzodipyrans as 5-HT2A/2C receptor probes. Bioorganic & Medicinal Chemistry, 10, 3301-3306.
Wouters, E., Walraed, J., Banister, S. D., & Stove, C. P. (2019). Insights into biased signaling at cannabinoid receptors: Synthetic cannabinoid receptor agonists. Biochemical Pharmacology, 169, 113623. https://doi.org/10.1016/j.bcp.2019.08.025
Wouters, E., Walraed, J., Robertson, M. J., Meyrath, M., Szpakowska, M., Chevigne, A., Skiniotis, G., & Stove, C. (2020). Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds. ACS Pharmacology & Translational Science, 3, 285-295.
Xia, Z., Gray, J. A., Compton-Toth, B. A., & Roth, B. L. (2003). A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction. The Journal of Biological Chemistry, 278, 21901-21908. https://doi.org/10.1074/jbc.M301905200
Zhang, R., & Xie, X. (2012). Tools for GPCR drug discovery. Acta Pharmacologica Sinica, 33, 372-384. https://doi.org/10.1038/aps.2011.173
Zhao, X., Jones, A., Olson, K. R. et al (2008). A homogeneous enzyme fragment complementation-based beta-arrestin translocation assay for high-throughput screening of G-protein-coupled receptors. Journal of Biomolecular Screening, 13, 737-747.